Clinical trial
Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
NCT06103266 is registered in ClinicalTrials.gov with J.P.S Henriques as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
- Lead sponsor
- J.P.S Henriques
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 31, 2024
- Completion date
- December 31, 2025
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.